Compare ORIC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | OPK |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.3M | 921.2M |
| IPO Year | 2020 | 2011 |
| Metric | ORIC | OPK |
|---|---|---|
| Price | $8.37 | $1.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 3 |
| Target Price | ★ $19.73 | $1.60 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.65 | $0.98 |
| 52 Week High | $14.93 | $1.60 |
| Indicator | ORIC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 33.01 | 35.91 |
| Support Level | $7.90 | $0.98 |
| Resistance Level | $13.89 | $1.25 |
| Average True Range (ATR) | 0.50 | 0.04 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 4.02 | 48.58 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.